Frequently Asked Questions

Just last week, the federal government finalized additional cuts to Medicare Advantage reimbursement rates in 2025—rates that industry giants like United Health and Humana had argued were insufficient to counter inflation and rising medical loss ratios. As a result, payors and their PBMs will attempt to cover their profits through Part D recoupments. Look out.

Medicare Advantage Has Been Lucrative

Medicare Advantage, a program offering comprehensive healthcare benefits to seniors through private insurers, has been a lucrative business for many companies. Indeed, MA insurers reported much higher gross margins per enrollee than insurers in other markets. These margins grew even fatter during the pandemic, when many patients delayed elective surgeries.

Medicare Advantage Margins are Now Shrinking

MA margins are now under pressure as patients return for procedures, increasing medical loss ratios. Likewise, the federal government is cutting reimbursement in coming years. As a result, the payors that have invested heavily in Medicare Advantage will rely even more heavily on their PBMs and SIUs to pad shrinking margins.

Payors Will Adapt to Government Cuts

The stock market loves industry giants like United Health because these companies have many different levers to boost performance and maintain profitability. With a diverse range of revenue streams, these industry giants possess the agility to adapt to changing market conditions.

For example, Special Investigative Units, or SIUs, routinely run budget surpluses from proceeds generated by Fraud, Waste and Abuse (FWA) activities. In other words, claims audit and monitoring activities are "self-funded" by recoupments, and represent a revenue opportunity.

PBM and Pharmacy Audits Will Fuel Recoupments

A notable aspect of insurers' recoupment strategies is the emphasis on pharmacy claims over medical claims. Pharmacy claims offer a more lucrative avenue for recoupment due to lower audit hurdles and the ability to recoup entire claims, irrespective of medication costs. PBMs wield significant power in this domain, making substantial profits through audits.

For example, routine office visits, or E&M coded claims, are low-dollar and are essentially bullet-proof from audit recoupment unless documentation is extremely poor. Similarly, higher-dollar medical procedure claims typically cannot be recouped unless medically unnecessary. In short, insurers and PBMs have much higher audit hurdles on medical billing and coding audits.

In contrast, PBMs recoup on pharmacy claims for immaterial reasons, including unsupported patient denials, failure to provide adequate "proof" of co-pay collection, such as credit card receipts or deposit slips, delivery issues, and other insignificant "violations" of one-sided PBM manuals. Importantly, PBMs recoup on the entire claim, irrespective that the pharmacy paid for the medication dispensed. That is all the more outrageous considering the rebates and spread pricing that PBMs receive on that medication in the first place!

Payors and PBMs Must Be Held Legally Accountable

PBM audit recoupments often violate the terms of the provider manual and network enrollment forms. It is critical that pharmacies know their audit rights and applicable law. Legal recourse may be necessary to challenge unjust practices and protect your rights.

MORE ARTICLES BY CATEGORY

Get a Free Case REVIEW

100% Confidential & Secure. Your details are safe with us.

We'll speak soon!

In the meantime, why not find out more about us or visit our blog.

Alternatively, give us a call at (800) 345 - 4125

Oops! Something went wrong while submitting the form.

Ketamine Clinics & Compounders Now the Focus of Increased DEA Enforcement

The DEA is increasingly targeting ketamine providers with record-keeping inspections and audits, making expert Medicare and DEA compliance defense essential to avoid steep fines and license risks.

Read More >>

HLA's Diana Yastrovskaya Featured on Live TV for PBM Expertise

The feature underscores HLA’s mission to elevate thought leadership within the healthcare space and provide trusted expertise on issues that directly impact patients, providers, and policymakers.

Read More >>

By Appointment Only: How DME Suppliers Can Prevent Unexpected DME License Revocations

DME suppliers can prevent unexpected and costly license revocations by strategically applying with a "By Appointment Only" designation. This article explores the common compliance trap of failing unannounced site visits due to conflicts between standard pharmacy operating hours and Medicare's "posted hours" requirement for DME suppliers. "By Appointment Only" status is a crucial safeguard, which suppliers can take to implement to protect their DME billing privileges.

Read More >>

Resolving Prescription “Red Flags” Is No Longer Optional: Federal Scrutiny Tightens on Controlled-Substance Dispensing

Pharmacists must resolve “red flags” under the Controlled Substances Act’s corresponding-responsibility requirements before dispensing controlled substances. Overlooking warning signs, such as cash-paid, high-dose opioid prescriptions—can now trigger False Claims Act liability and massive penalties, as demonstrated by Walgreens’ $350 million settlement in April 2025.

Read More >>